Article Sidebar
Published:
Jun 4, 2022DOI:
10.4314/tjpr.v21i4.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Amygdalin suppresses the proliferation, migration and EMT of gastric cancer cells by inhibiting TGF-β/Smad signal pathway
Abstract
Purpose: To investigate the effects of amygdalin on the proliferation, motility and epithelial mesenchymal transformation (EMT) of gastric cancer cells and to elucidate the operating mechanisms of action.
Methods: Gastric cancer AGS cells were treated with amygdalin (2.5, 5 and 10 mg/L). MTT and colony formation assays were used to investigate the effect of amygdalin on gastric cancer cell proliferation, while wound healing and Transwell assays were also carried out to determine its effect on the motility of gastric cancer cells. Immunoblot assays were used to investigate the effects of amygdalin on epithelial mesenchymal transformation (EMT) process and TGF-β/Smad pathway in gastric cancer cells.
Results: Treatment with amygdalin suppressed the proliferation of gastric cancer AGS cells (p < 0.05). Amygdalin suppressed the migration and invasion of AGS cells in vitro (p < 0.05). Additionally, amygdalin suppressed epithelial mesenchymal transformation (EMT) in AGS cells, and suppressed TGF-β/Smad pathway (p < 0.05), thereby suppressing growth, motility, and EMT in AGS cells.
Conclusion: Amygdalin may be useful for the treatment of gastric cancer; however, further studies are required ascertain this.
